| News
Roche and Novartis among most valuable companies
02.01.2018
The Basel pharmaceutical companies Roche and Novartis are among the 40 most valuable companies in the world, according to an EY study. American tech firms top the list.

Money. (Img: aleksandra85foto/pixabay)
The consultancy firm EY has again compared the 300 highest rated companies in the world – and once again the top 100 is dominated by US companies. Three Swiss companies were among the top 100: Nestlé ($264 billion/18th place), Roche ($213 billion/31st place) and Novartis ($195 billion/37th place).
“Although the European economy is now recovering sharply, Europe’s top companies still continue to play only a minor role on the world’s stock exchanges,” said Stefan Rösch, partner and head of transaction services at EY in Switzerland. “Although we are still well ahead with Nestlé and our two pharma companies, the opportunities offered by digitalization nonetheless need to be exploited more effectively in this country.”
Three US companies from the tech sector – Apple ($876 billion), Google’s owner Alphabet ($733 billion) and Microsoft ($661 billion) – captured the top three places. The Chinese internet giants Tencent and Alibaba, which doubled in value over the past year, also made it into the top 10. The US company Johnson & Johnson ($377 billion) was the highest ranked pharmaceutical company, coming in 10th place.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More